NYSE$TEVA

Teva Pharmaceutical Industries ADR · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Delivered solid performance despite macroeconomic headwinds and reached agreement in principle on nationwide opioids settlement

Teva reported Q2 2022 results with revenues of $3.8 billion. The company has reached an agreement in principle on a nationwide opioids settlement. The 2022 revenue outlook was revised due to foreign exchange headwinds and increased competition for COPAXONE, while reaffirming earnings and cash flow guidance.

  • Revenues of $3.8 billion
  • GAAP diluted loss per share of $0.21
  • Non-GAAP diluted EPS of $0.68
  • Free cash flow of $301 million

Headline financials

Total Revenue

$3.79B

Previous: $3.91B-3.2%
EPS (adj)

$0.68

Previous: $0.59+15.3%
Capital Expenditures

-$284M

Previous: -$263M-8.0%
Free Cash Flow

-$516M

Previous: -$56M-821.4%
Net Income

-$232M

Previous: $207M-212.1%
Operating Income

-$949M

Previous: $582M-263.1%
Gross Profit

$1.79B

Previous: $1.87B-4.2%
Cash & Equivalents

$2.06B

Previous: $2.44B-15.5%
Total Assets

$45.9B

Previous: $49.2B-6.6%
Stock-Based Comp

$39M

Previous: $29M+34.5%

Revenue & EPS history

Teva · Revenue · Quarterly

$3.79B

Q2 2022-3.2%vs Q2 2021
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Revenue by segment

Teva · $1.88B total across 3 segments · Q2 2022

  • Europe
    $1.17B
  • International Markets
    $454M
  • Other Activities
    $257M

Forward guidance

Teva revised its 2022 revenues outlook mainly due to continued foreign exchange headwinds and increased competition and foreign exchange fluctuations. Operating income, EBITDA, EPS and free cash flow were reaffirmed.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+0.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+0.7%

Avg return

30 days after

51%

38 / 74 earnings

Positive

+27.1%

Q2 2022

Best reaction

-34.1%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+11.9%+11.7%
Q4 2025+2.1%+9.2%+4.1%
Q3 2025+20.4%+18.6%+39.1%
Q2 2025+1.8%-5.1%+11.1%
Q1 2025+8.9%+11.4%+10.2%
Q4 2024-13.9%-19.4%-23.5%
Q3 2024-6.8%-7.5%-7.7%
Q2 2024+6.9%+1.6%+15.0%
Q1 2024+14.7%+21.0%+20.6%
Q4 2023+6.2%+5.5%+15.1%
Q3 2023-3.0%-2.4%+8.6%
Q2 2023+15.4%+16.2%+18.7%
Q1 2023-9.8%-11.3%-19.5%
Q4 2022-9.8%-5.4%-16.3%
Q3 2022-3.3%+3.7%-1.1%
Q2 2022+27.1%+30.5%+37.6%
Q1 2022-2.3%-8.1%+11.6%
Q4 2021+6.3%+2.8%-9.8%
Q3 2021-7.0%-1.7%-9.6%
Q2 2021+8.6%+10.4%+4.8%
Q1 2021+2.6%+4.2%+0.3%
Q4 2020-11.8%-13.2%-15.8%
Q3 2020-1.0%+4.5%+11.6%
Q2 2020+3.0%+0.6%-22.1%
Q1 2020+7.7%+9.0%+22.5%
Q4 2019+1.9%-0.9%-31.9%
Q3 2019+14.8%+18.6%+22.5%
Q2 2019+3.3%-0.6%-0.7%
Q1 2019-0.3%-4.1%-43.2%
Q4 2018-9.6%-6.0%-13.7%
Q3 2018+13.1%+15.6%+7.8%
Q2 2018-7.1%-2.5%-4.0%
Q1 2018-4.1%+1.6%+17.7%
Q4 2017-10.7%-11.2%-8.0%
Q3 2017-18.7%-16.6%+8.8%
Q2 2017-34.1%-16.2%-39.4%
Q1 2017+1.7%+1.3%-3.6%
Q4 2016+8.4%+9.4%+6.7%
Q3 2016-7.2%-6.0%-10.5%
Q2 2016+1.2%-6.2%-8.8%
Q1 2016+5.2%+1.7%+10.8%
Q4 2015-2.0%
Q3 2015-5.1%
Q2 2015-2.6%
Q1 2015+0.1%
Q3 2014+3.6%
Q4 2014+2.0%
Q2 2014-1.6%
Q1 2014+2.0%
Q4 2013-1.9%
Q3 2013-1.5%
Q2 2013-2.0%
Q1 2013+1.0%
Q4 2012+1.4%
Q3 2012+2.6%
Q2 2012-3.3%
Q1 2012-5.4%
Q4 2011+2.5%
Q3 2011+7.0%
Q2 2011+1.9%
Q1 2011+5.6%
Q4 2010+0.4%
Q3 2010+0.3%
Q2 2010-3.4%
Q1 2010+0.9%
Q4 2007+1.2%
Q4 2009+1.2%
Q3 2008-1.4%
Q3 2009-1.4%
Q2 2008-0.8%
Q2 2009-0.8%
Q1 2009-0.6%
Q1 2008-0.6%
Q4 2008-0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro